InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Chemomab Therapeutics Ltd.

CMMB Clue Score20
Israel Fiscal year ends December CIK 0001534248
$1.38 -0.72% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.38 −84.84% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Feb 2019. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2016Operating income−4.6Net income−4.7Fiscal year 2017Operating income−9.4Net income−9.8Fiscal year 2018Operating income−13.0Net income−13.8Fiscal year 2019Net income−27.1Fiscal year 2020Net income−6.0Fiscal year 2021Net income−12.5EPS, diluted0.06Fiscal year 2022Net income−27.6EPS, diluted0.12Fiscal year 2023Net income−24.2EPS, diluted0.10Fiscal year 2024Operating income−103.0Net income−13.9EPS, diluted0.04Fiscal year 2025Operating income−112.0Net income−9.0EPS, diluted0.02
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income −4.6 −9.4 −13.0 n/a n/a n/a n/a n/a −103.0 −112.0
Net income −4.7 −9.8 −13.8 −27.1 −6.0 −12.5 −27.6 −24.2 −13.9 −9.0
Growth
EPS, diluted n/a n/a n/a n/a n/a 0.06 0.12 0.10 0.04 0.02

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−3.7Capital expenditure−0.1Free cash flow−3.8Fiscal year 2017Operating cash flow−8.5Capital expenditure−0.0Free cash flow−8.5Fiscal year 2018Operating cash flow−14.2Capital expenditure−0.2Free cash flow−14.4Fiscal year 2019Operating cash flow−16.5Capital expenditure−0.1Free cash flow−16.6Fiscal year 2020Operating cash flow−5.2Capital expenditure−0.0Free cash flow−5.3Fiscal year 2021Operating cash flow−12.4Capital expenditure−0.2Free cash flow−12.6Fiscal year 2022Operating cash flow−20.4Capital expenditure−0.1Free cash flow−20.4Fiscal year 2023Operating cash flow−23.6Capital expenditure−0.0Free cash flow−23.6Fiscal year 2024Operating cash flow−15.4Capital expenditure0.0Free cash flow−15.4Fiscal year 2025Operating cash flow−11.1Capital expenditure−0.0Free cash flow−11.1
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −3.7 −8.5 −14.2 −16.5 −5.2 −12.4 −20.4 −23.6 −15.4 −11.1
Capital expenditure −0.1 −0.0 −0.2 −0.1 −0.0 −0.2 −0.1 −0.0 0.0 −0.0
Free cash flow −3.8 −8.5 −14.4 −16.6 −5.3 −12.6 −20.4 −23.6 −15.4 −11.1
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2016Cash4.6Shareholders’ equity3.3Fiscal year 2017Cash1.5Shareholders’ equity−0.6Fiscal year 2018Cash7.5Shareholders’ equity9.8Fiscal year 2019Cash17.6Shareholders’ equity12.4Fiscal year 2020Cash11.7Shareholders’ equity10.8Fiscal year 2021Cash15.2Shareholders’ equity61.5Fiscal year 2022Cash13.5Shareholders’ equity36.2Fiscal year 2023Cash9.3Shareholders’ equity17.0Fiscal year 2024Cash6.1Shareholders’ equity13.5Fiscal year 2025Cash7.6Shareholders’ equity12.3
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 4.6 1.5 7.5 17.6 11.7 15.2 13.5 9.3 6.1 7.6
Shareholders’ equity 3.3 −0.6 9.8 12.4 10.8 61.5 36.2 17.0 13.5 12.3

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Spending
n/a n/a 2.3% 0.0% 0.0% n/a n/a n/a n/a n/a
Returns
−143.9% n/a −140.7% −219.2% −55.1% −20.3% −76.3% −142.5% −103.0% −72.9%
n/a −469.9% −109.7% n/a n/a n/a n/a n/a n/a n/a
Balance and payout
n/a 129.2% 108.7% n/a n/a n/a n/a n/a n/a n/a